Molecular pathology of breast apocrine carcinomas: A protein expression signature specific for benign apocrine metaplasia

FEBS Letters

Volumn 580, Issue 12, 2006, Pages 2935-2944

  Celis, Julio E ^a,b   Gromova, Irina ^a,b   Gromov, Pavel ^a,b   Moreira, José M A ^a,b   Cabezón, Teresa ^a,b   Friis, Esbern ^a,c   Rank, Fritz ^a,c  

^a Institute of Cancer Biolog   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Apocrine metaplasia; Benign apocrine metaplasia signature; Chemoprevention; Invasive apocrine carcinomas; Pre malignant apocrine lesions; Proteomics

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN; CELECOXIB; CELL PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVINOLIN; NAFAZATROM; PRAVASTATIN; PROTEIN P53; PROTEIN S100A9; PSORIASIN; ROFECOXIB; SALAZOSULFAPYRIDINE; TUMOR MARKER; UNCLASSIFIED DRUG;

APOCRINE CARCINOMA; BENIGN TUMOR; BREAST CARCINOMA; BREAST CYST; CANCER GROWTH; CANCER INVASION; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; DISEASE COURSE; DRUG MECHANISM; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; METAPLASIA; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SHORT SURVEY;

APOCRINE GLANDS; BREAST NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; NEOPLASM PROTEINS;

EID: 33646556150     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.03.080     Document Type: Short Survey

References (85)

1. Mallon E., Osin P., Nasiri N., Blain I., Howard B., and Gusterson B. The basic pathology of human breast cancer. J. Mammary Gland Biol. Neoplasia 5 (2000) 139-163
2. d'Amore E.S., Terrier-Lacombe M.J., Travagli J.P., Friedman S., and Contesso G. Invasive apocrine carcinoma of the breast: a long term follow-up study of 34 cases. Breast Cancer Res. Treat. 12 (1988) 37-44
3. Bundred N.J., Walker R.A., Everington D., White G.K., Stewart H.J., and Miller W.R. Is apocrine differentiation in breast carcinoma of prognostic significance?. Br. J. Cancer 62 (1990) 113-117
4. Raju U., Ma C.K., and Shaw A. Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study. Mod. Pathol. 6 (1993) 516-520
5. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., and Botstein D. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
6. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., and Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347 (2002) 1999-2009
7. Weigelt B., Hu Z., He X., Livasy C., Carey L.A., Ewend M.G., Glas A.M., Perou C.M., and Van't Veer L.J. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 65 (2005) 9155-9158
8. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., Talantov D., Timmermans M., Meijer-van Gelder M.E., Yu J., Jatkoe T., Berns E.M., Atkins D., and Foekens J.A. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
9. Pawitan Y., Bjohle J., Amler L., Borg A.L., Egyhazi S., Hall P., Han X., Holmberg L., Huang F., Klaar S., Liu E.T., Miller L., Nordgren H., Ploner A., Sandelin K., Shaw P.M., Smeds J., Skoog L., Wedren S., and Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 7 (2005) R953-R964
10. Jansen M.P., Foekens J.A., van Staveren I.L., Dirkzwager-Kiel M.M., Ritstier K., Look M.P., Meijer-van Gelder M.E., Sieuwerts A.M., Portengen H., Dorssers L.C., Klijn J.G., and Berns E.M. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Oncol. 23 (2005) 732-740
11. Lonning P.E., Sorlie T., and Borresen-Dale A.L. Genomics in breast cancertherapeutic implications. Nat. Clin. Pract. Oncol. 2 (2005) 26-33
12. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lonning P.E., Brown P.O., Borresen-Dale A.L., and Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100 (2003) 8418-8423
13. Farmer P., Bonnefoi H., Becette V., Tubiana-Hulin M., Fumoleau P., Larsimont D., Macgrogan G., Bergh J., Cameron D., Goldstein D., Duss S., Nicoulaz A.L., Brisken C., Fiche M., Delorenzi M., and Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24 (2005) 4660-4671
14. Japaze H., Emina J., Diaz C., Schwam R.J., Gercovich N., Demonty G., Morgenfeld E., Rivarola E., Gil Deza E., and Gercovich F.G. 'Pure' invasive apocrine carcinoma of the breast: a new clinicopathological entity?. Breast 14 (2005) 3-10
15. Celis J.E., and Gromov P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3 (2003) 9-15
16. Celis J.E., Gromov P., Gromova I., Moreira J.M., Cabezon T., Ambartsumian N., Grigorian M., Lukanidin E., Thor Straten P., Guldberg P., Bartkova J., Bartek J., Lukas J., Lukas C., Lykkesfeldt A., Jaattela M., Roepstorff P., Bolund L., Orntoft T., Brunner N., Overgaard J., Sandelin K., Blichert-Toft M., Mouridsen H., and Rank F.E. Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. Mol. Cell. Proteomics 2 (2003) 369-377
17. Celis J.E., Gromov P., Cabezon T., Moreira J.M., Ambartsumian N., Sandelin K., Rank F., and Gromova I. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol. Cell. Proteomics 3 (2004) 327-344
18. Celis J.E., Moreira J.M., Gromova I., Cabezon T., Ralfkiaer U., Guldberg P., Straten P.T., Mouridsen H., Friis E., Holm D., Rank F., and Gromov P. Towards discovery-driven translational research in breast cancer. FEBS J. 272 (2005) 2-15
19. Celis J.E., Moreira J.M., Cabezon T., Gromov P., Friis E., Rank F., and Gromova I. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol. Cell. Proteomics 4 (2005) 492-522
20. Celis J.E., Gromov P., Moreira J.M., Cabezon T., Friis E., Vejborg I.M., Proess G., Rank F., and Gromova I. Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype. Mol. Cell. Proteomics 5 (2005) 462-483
21. Allred D.C., Mohsin S.K., and Fuqua S.A. Histological and biological evolution of human premalignant breast disease. Endocr. Relat. Cancer 8 (2001) 47-61
22. Miller W.R., Telford J., Dixon J.M., and Shivas A.A. Androgen metabolism and apocrine differentiation in human breast cancer. Breast Cancer Res. Treat. 5 (1985) 67-73
23. Eusebi V., Millis R.R., Cattani M.G., Bussolati G., and Azzopardi J.G. Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am. J. Pathol. 123 (1986) 532-541
24. Abati A.D., Kimmel M., and Rosen P.P. Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am. J. Clin. Pathol. 94 (1990) 371-377
25. O'Malley F.P., Page D.L., Nelson E.H., and Dupont W.D. Ductal carcinoma in situ of the breast with apocrine cytology: definition of a borderline category. Hum. Pathol. 25 (1994) 164-168
26. Durham J.R., and Fechner R.E. The histologic spectrum of apocrine lesions of the breast. Am. J. Clin. Pathol. 113 (2000) S3-S18
27. Leal C., Henrique R., Monteiro P., Lopes C., Bento M.J., De Sousa C.P., Lopes P., Olson S., Silva M.D., and Page D.L. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Hum. Pathol. 32 (2001) 487-493
28. Page D.L. Apocrine carcinomas of the breast. Breast 14 (2005) 1-2
29. Wellings S.R., and Alpers C.E. Apocrine cystic metaplasia: subgross pathology and prevalence in cancer-associated versus random autopsy breasts. Hum. Pathol. 18 (1987) 381-386
30. Ness J.C., Sedghinasab M., Moe R.E., and Tapper D. Identification of multiple proliferative growth factors in breast cyst fluid. Am. J. Surg. 166 (1993) 237-243
31. Bruzzi P., Dogliotti L., Naldoni C., Bucchi L., Costantini M., Cicognani A., Torta M., Bruzzi G.F., and Angeli A. Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. BMJ 314 (1997) 925-928
32. Angeli A., Dogliotti L., Naldoni C., Orlandi F., Puligheddu B., Caraci P., Bucchi L., Torta M., and Bruzzi P. Steroid biochemistry and categorization of breast cyst fluid: relation to breast cancer risk. J. Steroid. Biochem. Mol. Biol. 49 (1994) 333-339
33. Dupont W.D., Parl F.F., Hartmann W.H., Brinton L.A., Winfield A.C., Worrell J.A., Schuyler P.A., and Plummer W.D. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71 (1993) 1258-1265
34. O'Malley F.P., and Bane A.L. The spectrum of apocrine lesions of the breast. Adv. Anat. Pathol. 1 (2004) 1-9
35. Ahmed A. Calcification in human breast carcinomas: ultrastructural observations. J. Pathol. 117 (1975) 247-251
36. Eusebi V., Damiani S., Losi L., and Millis R.R. Apocrine differentiation in breast epithelium. Adv. Anat. Pathol. 4 (1997) 139-155
37. Jones C., Damiani S., Wells D., Chaggar R., Lakhani S.R., and Eusebi V. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am. J. Pathol. 158 (2001) 207-214
38. Wellings S.R., Jensen H.M., and Marcum R.G. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J. Natl. Cancer. Inst. 55 (1975) 231-273
39. Yates A.J., and Ahmed A. Apocrine carcinoma and apocrine metaplasia. Histopathology 13 (1988) 228-231
40. Haagensen Jr. D.E. Is cystic disease related to breast cancer?. Am. J. Surg. Pathol. 15 (1991) 687-694
41. Wells C.A., McGregor I.L., Makunura C.N., Yeomans P., and Davies J.D. Apocrine adenosis: a precursor of aggressive breast cancer?. J. Clin. Pathol. 48 (1995) 737-742
42. Page D.L., Dupont W.D., and Jensen R.A. Papillary apocrine change of the breast: associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 5 (1996) 29-32
43. Viacava P., Naccarato A.G., and Bevilacqua G. Apocrine epithelium of the breast: does it result from metaplasia?. Virchows Arch. 431 (1997) 205-209
44. Trenkić S., Katić V., Pashalina M., Živković V., Milintijević M., and Kostov M. The histologic spectrum of apocrine lesions of the breast. Arch. Oncol. 12 (2004) 61-65
45. Selim A.G., El-Ayat G., Naase M., and Wells C.A. C-myc oncoprotein expression and gene amplification in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Breast 11 (2002) 466-472
46. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
47. Hughes L.E., and Bundred N.J. Breast macrocysts. World J. Surg. 13 (1989) 711-714
48. Dixon J.M., Scott W.N., and Miller W.R. Natural history of cystic disease: the importance of cyst type. Br. J. Surg. 72 (1985) 190-192
49. Enriori C.L., Novelli J.E., Cremona M.D.C., Hirsig R.J.P., and Enriori P.J. Biochemical study of cyst fluid in human breast cystic disease. Breast Cancer Res. Treat. 24 (1992) 1-9
50. Miller W.R., Scott W.N., Harris W.H., and Wang D. Using biological measurements, can patients with benign breast disease who are at high risk for breast cancer be identified?. Cancer Detect. Prev. 16 (1992) 99-106
51. Tsung J.S., Wang T.Y., Wang S.M., and Yang P.S. Cytological and biochemical studies of breast cyst fluid. Breast 14 (2005) 37-41
52. Page D.L., Vander Zwaag R., Rogers L.W., Williams L.T., Walker W.E., and Hartmann W.H. Relation between component parts of fibrocystic disease complex and breast cancer. J. Natl. Cancer Inst. 61 (1978) 1055-1063
53. Tavassoli F.A., and Norris H.J. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod. Pathol. 7 (1994) 813-818
54. Rosai J. Ackerman's Surgical Pathology (1996), Mosby-Year Book, New York pp. 1565-1659
55. Selim A.G., and Wells C.A. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors. J. Clin. Pathol. 52 (1999) 838-841
56. Moriya T., Sakamoto K., Sasano H., Kawanaka M., Sonoo H., Manabe T., and Ito J. Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases. Mod. Pathol. 13 (2000) 13-18
57. Scawn R., and Shousha S. Morphologic spectrum of estrogen receptor-negative breast carcinoma. Arch. Pathol. Lab. Med. 126 (2002) 325-330
58. de Nigris F., Lerman L.O., and Napoli C. New insights in the transcriptional activity and coregulator molecules in the arterial wall. Int. J. Cardiol. 86 (2002) 153-168
59. Morikawa S., Murakami T., Yamazaki H., Izumi A., Saito Y., Hamakubo T., and Kodama T. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J. Atheroscler. Thromb. 12 (2005) 121-131
60. Muller-Decker K., Berger I., Ackermann K., Ehemann V., Zoubova S., Aulmann S., Pyerin W., and Furstenberger G. Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin5 promoter-driven overexpression of cyclooxygenase-2. Am. J. Pathol. 166 (2005) 575-584
61. Papotti M., Eusebi V., Gugliotta P., and Bussolati G. Immunohistochemical analysis of benign and malignant papillary lesions of the breast. Am. J. Surg. Pathol. 7 (1983) 451-461
62. Honma N., Takubo K., Akiyama F., Sawabe M., Arai T., Younes M., Kasumi F., and Sakamoto G. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology 47 (2005) 195-201
63. Mossler J.A., Barton T.K., Brinkhous A.D., McCarty K.S., Moylan J.A., and McCarty Jr. K.S. Apocrine differentiation in human mammary carcinoma. Cancer 46 (1980) 2463-2471
64. Eusebi V., Betts C., Haagensen Jr. D.E., Gugliotta P., Bussolati G., and Azzopardi J.G. Apocrine differentiation in lobular carcinoma of the breast: a morphologic, immunologic, and ultrastructural study. Hum. Pathol. 15 (1984) 134-140
65. Celis J.E., Celis P., Palsdottir H., Ostergaard M., Gromov P., Primdahl H., Orntoft T.F., Wolf H., Celis A., and Gromova I. Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol. Cell. Proteomics 1 (2002) 269-279
66. Madsen P., Rasmussen H.H., Leffers H., Honoré B., Dejgaard K., Olsen E., Kiil J., Walbum E., Andersen A.H., Basse B., Lauridsen J.B., Ratz G.P., Celis A., Vandekerckhove J., and Celis J.E. Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin. J. Invest. Dermatol. 97 (1991) 701-712
67. Nacken W., Roth J., Sorg C., and Kerkhoff C. S100A9/S100A8: myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc. Res. Tech. 60 (2003) 569-580
68. Heizmann C.W., Fritz G., and Schafer B.W. S100 proteins: structure, functions and pathology. Front. Biosci. 7 (2002) 1356-1368
69. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc. Res. Tech. 60 (2003) 540-551
70. Krop I., Marz A., Carlsson H., Li X., Bloushtain-Qimron N., Hu M., Gelman R., Sabel M.S., Schnitt S., Ramaswamy S., Kleer C.G., Enerback C., and Polyak K. A putative role for psoriasin in breast tumor progression. Cancer Res. 65 (2005) 11326-11334
71. Eckert R.L., Broome A.M., Ruse M., Robinson N., Ryan D., and Lee K. S100 proteins in the epidermis. J. Invest. Dermatol. 123 (2004) 23-33
72. Melle C., Ernst G., Schimmel B., Bleul A., Koscielny S., Wiesner A., Bogumil R., Moller U., Osterloh D., Halbhuber K.J., and von Eggeling F. A technical triade for proteomic identification and characterization of cancer biomarkers. Cancer Res. 64 (2004) 4099-4104
73. Hermani A., Hess J., De Servi B., Medunjanin S., Grobholz R., Trojan L., Angel P., and Mayer D. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin. Cancer Res. 11 (2005) 5146-5152
74. +-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents. Prostaglandins Leukot. Essent. Fatty Acids 67 (2002) 461-465
75. Moreno J., Krishnan A.V., Swami S., Nonn L., Peehl D.M., and Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 65 (2005) 7917-7925
76. Hull M.A. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?. Eur. J. Cancer 41 (2005) 1854-1863
77. Demierre M.F., Higgins P.D., Gruber S.B., Hawk E., and Lippman S.M. Statins and cancer prevention. Nat. Rev. Cancer 5 (2005) 930-942
78. Swanson K.M., and Hohl R.J. Anti-cancer therapy: targeting the mevalonate pathway. Curr. Cancer Drug Targets 6 (2006) 15-37
79. Subbaramaiah K., Norton L., Gerald W., and Dannenberg A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 277 (2002) 18649-18657
80. West M., Blanchette C., Dressman H., Huang E., Ishida S., Spang R., Zuzan H., Olson Jr. J.A., Marks J.R., and Nevins J.R. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci. USA 98 (2001) 11462-11467
81. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., and Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
82. Huang E., Cheng S.H., Dressman H., Pittman J., Tsou M.H., Horng C.F., Bild A., Iversen E.S., Liao M., Chen C.M., West M., Nevins J.R., and Huang A.T. Gene expression predictors of breast cancer outcomes. Lancet 361 (2003) 1590-1596
83. Anderson L., and Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18 (1997) 533-537
84. Celis J.E., Kruhoffer M., Gromova I., Frederiksen C., Ostergaard M., Thykjaer T., Gromov P., Yu J., Palsdottir H., Magnusson N., and Orntoft T.F. Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett. 480 (2000) 2-16
85. Østergaard M., Wolf H., Orntoft T.F., and Celis J.E. Psoriasin (S100A7): a putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. Electrophoresis 20 2 (1999) 349-354